Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Dec;5(6):E121-4.
doi: 10.3978/j.issn.2078-6891.2014.079.

A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression

Michele Panebianco  1 , Moira Ragazzi  1 , Nuria Maria Asensio  1 , Maria Pagano  1 , Roberta Gnoni  1 , Corrado Boni  1
Affiliations
Case Reports

A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression

Michele Panebianco et al. J Gastrointest Oncol. 2014 Dec.

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and is the third most common cause of death from cancer. Sorafenib is the only drug which improves survival in first line advanced HCC. Sorafenib has been associated with several dermatologic toxicities and toxic effects have been related to a better treatment response. We report the case of a well-circumscribed panniculitis and necrotizing vasculitis due to sorafenib, appeared in disease progression in a man affected by advanced HCC.

Keywords: Sorafenib; hepatocellular carcinoma (HCC); panniculitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cutaneous lesions after three months of sorafenib treatment.
Figure 2
Figure 2
(A) Dermal and subcutaneous inflammation (2×); (B) epidermis is unaffected. Superficial dermal inflammatory infiltrate is moderate and numerous granulocyte neutrophils are evident (10×); (C) subcutaneous fat shows a heavy inflammatory infiltrate consistent with panniculitis; (D) necrotizing vasculitis with vessels wall fibrinoid necrosis (arrows) and (E) vascular thrombosis (arrow) (20×; 40×).
See this image and copyright information in PMC

References

    1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917. - PubMed
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. - PubMed
    1. Bruix J, Sherman M, Practice Guidelines Committee, et al . Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. - PubMed
    1. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. - PubMed
    1. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47. - PubMed

Publication types